CRISPR Therapeutics AG (CRSP) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2022
Loading P/E history...
CRSP Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, CRISPR Therapeutics AG (CRSP) trades at a price-to-earnings ratio of -8.5x, with a stock price of $55.08 and trailing twelve-month earnings per share of $-5.92.
The current P/E is 116% below its 5-year average of 52.7x. Over the past five years, CRSP's P/E has ranged from a low of 17.1x to a high of 159.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CRSP trades at a 138% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, CRSP trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CRSP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CRSP P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $109B | 27.9 | 3.37 | +837%Best | |
| $75B | 17.4Lowest | 2.75Best | +8% | |
| $22B | 26.2 | 6.18 | +171% | |
| $176B | 26.7 | 12.62 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CRSP Historical P/E Data (2019–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q1 | $62.77 | $3.61 | 17.4x | -67% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $75.78 | $4.42 | 17.1x | -67% |
| FY2021 Q3 | $111.93 | $4.73 | 23.7x | -55% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $161.89 | $5.08 | 31.9x | -40% |
| FY2020 Q2 | $73.49 | $0.46 | 159.8x | +203% | |
| FY2020 Q1 | $42.41 | $0.75 | 56.5x | +7% | |
| FY2019 Q4 | $60.91 | $0.97 | 62.8x | +19% |
Average P/E for displayed period: 52.7x
See CRSP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRSP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRSP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCRSP — Frequently Asked Questions
Quick answers to the most common questions about buying CRSP stock.
Is CRSP stock overvalued or undervalued?
CRSP trades at -8.5x P/E, below its 5-year average of 52.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CRSP's valuation compare to peers?
CRISPR Therapeutics AG P/E of -8.5x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is CRSP's PEG ratio?
CRSP PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2019-2022.